Business Wire

Dole, Employees Give to Restore and Rebuild Devastated Central America

Share

On November 3, 2020 Hurricane Eta made landfall in Central America as a powerful Category 4 storm. Just two weeks later Hurricane Iota, a Category 5 storm followed nearly the same path through the region, unleashing heavy rains, winds, massive flooding and severe landslides, causing widespread destruction.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005255/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Replanting bananas in Honduras. Restoring fields and livelihoods destroyed by Hurricanes Eta and Iota in November 2020. (Photo: Business Wire)

Communities and towns in Honduras and Guatemala - many that support Dole farms and workers – were leveled in the wake. Though Dole was able to successfully evacuate its workers and families prior to the hurricanes’ arrivals, many others were not as fortunate and lost their lives or livelihoods, their possessions and their crops. In the aftermath, water was needed to drink, homes were in need of repair, and clothes, supplies and appliances in need of replacement.

As an organization closely connected to these communities through the banana industry, Dole swiftly moved to lend aid and resources. But not just the company as an entity stepped in, many Dole employees, partners, and public supporters —no matter how far physically from these communities — also contributed their own time and their own funds to help.

In these six months since the hurricanes’ devastation much has been accomplished.

  • Dole employees, the company and the public together raised, collected and donated a quarter of a million dollars to purchase food baskets of essential food items -- red beans, rice, corn flour, vegetable oil and powdered milk, capable of feeding a family of five for a month. These food baskets were distributed to 10,000 families in-need in communities surrounding our operations and through relief organizations CEPUDO and the Cortés Chamber of Commerce with established distribution networks in other areas.
  • The Red Cross of Honduras received donations of dozens of boxes of clothing and footwear contributed by Dole employees in North America and Dole’s Standard Fruit De Honduras. In addition to 500,000 Lempiras ($20,000US) to help those in need and provide support.
  • Dole provided use of company machinery and heavy equipment to repair public services, bridges, roads, and highways.
  • Dole allocated space on southbound vessels to humanitarian organizations importing and distributing disaster relief goods and equipment.
  • With many banana production areas completely destroyed, Dole, as a major employer of choice in the region, has expedited efforts to restore banana plantations to full production. Farm land preparation takes time and is completely tailored to the conditions of each agricultural area, yet returning jobs and paychecks to the areas quickly is critical.

“I cannot sufficiently convey the heartbreaking destruction these communities endured,” said Nelson Montoya President of Dole Fresh Fruit North America. “However, this catastrophe did not defeat them. The compassion, resiliency and camaraderie of all those on our team in Honduras and Guatemala has been inspiring to me. We will continue to invest in getting everyone back on their feet.”

The investment reached a significant milestone in the rehabilitation process in Honduras, with the first planting of new banana fields at Mendez Farm, Barimasa Zone on May 4, followed closely with planting at Copote Farm in the Isletas Zone and most recently the Palo Verde farm in the Coyoles Zone.

As the company works to restore production volumes derived from these devastated areas in Honduras and Guatemala, Dole expects customers will begin receiving Dole premium fruit from these regions in January 2022.

About Dole Food Company

Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

William Goldfield
818-874-4647
william.goldfield@dole.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye